QIAGEN launches therascreen BRAF test as companion diagnostic to a BRAFTOVI® (encorafenib) based regimen in metastatic colorectal cancer
• U.S. FDA approves therascreen BRAF V600E RGQ PCR assay as companion diagnostic • Test will help identify patients elig…